Nasdaq
$2.85▼ 0.35%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $92.0MShares out 32.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.21After-hours26.09.22 05:058-KKey event#●●●#●●●
Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics has entered into Amendment No. 2 to its 2021 merger agreement with Chronix. The amendment clarifies the 10% royalty payment terms for CNI Monitor net sales and establishes that upon a future sale of the CNI Monitor business, the company will make a final payment of 10% of the gross proceeds, effectively terminating all ongoing royalty obligations.…more
$2.85-0.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.10After-hours26.08.11 05:1410-QEarnings
Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc.는 2026년 6월 30일 종료된 분기에 대한 10-Q 보고서를 제출하였습니다. 해당 공시는 회사의 재무 상태와 운영 결과에 대한 경영진의 인증을 포함하고 있으며, 주요 사업 활동으로 키트 제품 판매 및 실험실 서비스 운영을 지속하고 있습니다.…more
$2.85-0.35%vs prev closeView filingShare - 8.10After-hours26.08.11 05:108-KKey event
Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics는 2026년 2분기 매출 23만 9천 달러, 순손실 1,130만 달러(주당 0.31달러)를 기록했습니다. 주력 제품인 GraftAssureDx에 대해 FDA로부터 추가 정보 요청(AIR)을 받았으며, 회사는 180일 이내에 답변을 제출해야 합니다.…more
$2.85-0.35%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 21:00#●●●#●●●#●●●
iMDx Appoints New Sales Leader Ahead of GraftAssureDx Launch
Insight Molecular Diagnostics has appointed a new Senior Vice President of Sales to lead commercialization efforts for its GraftAssureDx product. The diagnostic tool is currently awaiting FDA authorization, and the company is preparing for a market launch.…more
$2.85-0.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.12Pre-market26.10.12 21:00
●●●●●●●● ●●●●● ●●●●●●
iMDx will participate in the U.S. Bancorp I BTIG Kidney Health Forum to discuss the clinical applications of its diagnostic technology with key opinion leaders. The event includes management meetings with investors to highlight the company's diagnostic solutions.…more
$2.85-0.35%vs prev close - 9.21After-hours26.09.22 05:08
●●●●●●●● ●●●●● ●●●●●●
iMDx has amended its merger agreement with Chronix to replace the ongoing 10% royalty on CNI Monitor with a one-time 10% payment upon the sale of the asset. This change effectively terminates the ongoing royalty obligation once the CNI Monitor sale payment is made.…more
$2.85-0.35%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report